DRI Healthcare Trust (DHT-UN) Q3 2024 earnings summary

Executive summary

• Management changes included new CEO and CFO appointments, with a focus on enhanced governance and internal controls to support growth.

• Achieved strong portfolio growth and deal execution, highlighted by significant royalty transactions for Casgevy and sebetralstat, deploying $162 million.

• Expanded leadership team and governance to drive continued growth and internalization assessment, with a decision expected in early 2025.

• Focused on capital allocation and unitholder returns, with quarterly distribution of $0.085 per unit declared.

Financial highlights

• Normalized total cash receipts reached $38.9 million, up 54% year-over-year.

• Total income was $41.6 million, a 22% increase over the same quarter in 2023.

• Adjusted EBITDA was $31.3 million, up 53% year-over-year, with an 80% margin (84% for the last twelve months).

• Adjusted cash earnings per unit were $0.45 for the quarter and $2.44 for the last 12 months.

• Cash and cash equivalents stood at $89.4 million as of September 30, 2024.

Outlook and guidance

• Pipeline of over $3 billion in potential opportunities under active evaluation.

• Increased five-year capital deployment target to over $1.25 billion, up from $650–$750 million at IPO.

• High-teens royalty income CAGR expected through 2025, mid- to high-single digit CAGR through 2030, excluding new transactions.

• Guidance updates will shift to a periodic cadence, with royalty income target guidance likely to be updated in Q4.

• Anticipates first Casgevy royalty payment in January 2025; sebetralstat royalties expected post-launch, pending FDA approval in June 2025.